| 3.15 0.41 (14.96%) | 08-19 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 3.69  |
1-year : | 4.31 |
| Resists | First : | 3.16 |
Second : | 3.69 |
| Pivot price | 2.45 |
|||
| Supports | First : | 2.49 |
Second : | 2.08 |
| MAs | MA(5) : | 2.75 |
MA(20) : | 2.38 |
| MA(100) : | 2.44 |
MA(250) : | 2.23 |
|
| MACD | MACD : | 0.1 |
Signal : | 0 |
| %K %D | K(14,3) : | 93.1 |
D(3) : | 92.5 |
| RSI | RSI(14): 79.2 |
|||
| 52-week | High : | 3.59 | Low : | 1.21 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ABOS ] has closed above the upper band by 15.7%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 65.8% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 0 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 3.16 - 3.18 | 3.18 - 3.19 |
| Low: | 2.76 - 2.77 | 2.77 - 2.79 |
| Close: | 3.13 - 3.15 | 3.15 - 3.17 |
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
Sat, 15 Aug 2026
Acumen Pharmaceuticals Inc (ABOS) Stock News Today - TradingKey
Wed, 12 Aug 2026
Acumen Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:ABOS) 2026-08-12 - Seeking Alpha
Wed, 05 Aug 2026
Alzheimer’s drug developer Acumen sets Aug. 12 webcast at 8 a.m. - Stock Titan
Fri, 31 Jul 2026
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Wed, 15 Jul 2026
All You Need to Know About Acumen Pharmaceuticals (ABOS) Rating Upgrade to Buy - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 72 (M) |
| Shares Float | 37 (M) |
| Held by Insiders | 6.8 (%) |
| Held by Institutions | 67.8 (%) |
| Shares Short | 2,810 (K) |
| Shares Short P.Month | 1,890 (K) |
| EPS | -1.86 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.21 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -42.4 % |
| Return on Equity (ttm) | -93.3 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.46 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.59 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -106 (M) |
| Levered Free Cash Flow | -67 (M) |
| PE Ratio | -1.71 |
| PEG Ratio | 0 |
| Price to Book value | 2.6 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.16 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|